GM Advisory Group Inc. Takes $290,000 Position in Merck & Co. (MRK)

GM Advisory Group Inc. purchased a new stake in Merck & Co. (NYSE:MRK) in the fourth quarter, according to its most recent Form 13F filing with the SEC. The institutional investor purchased 5,155 shares of the company’s stock, valued at approximately $290,000.

Other hedge funds and other institutional investors have also modified their holdings of the company. American International Group Inc. lifted its stake in Merck & Co. by 992.8% during the fourth quarter. American International Group Inc. now owns 9,152,305 shares of the company’s stock valued at $515,000,000 after buying an additional 8,314,765 shares in the last quarter. Janus Henderson Group PLC lifted its stake in Merck & Co. by 172.3% during the third quarter. Janus Henderson Group PLC now owns 6,705,564 shares of the company’s stock valued at $429,347,000 after buying an additional 4,243,246 shares in the last quarter. Capital International Investors lifted its stake in Merck & Co. by 55.3% during the third quarter. Capital International Investors now owns 9,623,382 shares of the company’s stock valued at $616,185,000 after buying an additional 3,428,400 shares in the last quarter. Vanguard Group Inc. lifted its stake in Merck & Co. by 1.7% during the second quarter. Vanguard Group Inc. now owns 194,144,317 shares of the company’s stock valued at $12,442,709,000 after buying an additional 3,312,459 shares in the last quarter. Finally, Stifel Financial Corp lifted its stake in Merck & Co. by 95,700.4% during the third quarter. Stifel Financial Corp now owns 3,281,163 shares of the company’s stock valued at $210,016,000 after buying an additional 3,277,738 shares in the last quarter. 74.60% of the stock is owned by institutional investors.

How to Become a New Pot Stock Millionaire

In related news, insider Weir Mirian M. Graddick sold 24,000 shares of the stock in a transaction that occurred on Monday, April 16th. The stock was sold at an average price of $58.00, for a total value of $1,392,000.00. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, Director Wendell P. Weeks sold 5,000 shares of the stock in a transaction that occurred on Friday, February 9th. The stock was sold at an average price of $53.57, for a total value of $267,850.00. Following the completion of the transaction, the director now owns 5,100 shares in the company, valued at approximately $273,207. The disclosure for this sale can be found here. Corporate insiders own 0.32% of the company’s stock.

A number of analysts have commented on MRK shares. Barclays raised shares of Merck & Co. from an “equal weight” rating to an “overweight” rating and upped their price objective for the company from $62.00 to $64.00 in a research note on Thursday, April 5th. SunTrust Banks raised shares of Merck & Co. from a “hold” rating to a “buy” rating and upped their price objective for the company from $54.00 to $72.00 in a research note on Tuesday, January 16th. ValuEngine raised shares of Merck & Co. from a “hold” rating to a “buy” rating in a research note on Wednesday, January 10th. BMO Capital Markets upped their price objective on shares of Merck & Co. from $68.00 to $72.00 and gave the company an “outperform” rating in a research note on Wednesday, January 17th. Finally, DZ Bank raised shares of Merck & Co. from a “hold” rating to a “buy” rating in a research note on Tuesday, February 13th. One equities research analyst has rated the stock with a sell rating, seven have issued a hold rating and fifteen have given a buy rating to the company’s stock. Merck & Co. has an average rating of “Buy” and a consensus price target of $66.83.

NYSE MRK opened at $59.27 on Wednesday. The company has a quick ratio of 1.06, a current ratio of 1.33 and a debt-to-equity ratio of 0.62. The company has a market capitalization of $154,141.17, a PE ratio of 14.89, a P/E/G ratio of 2.41 and a beta of 0.77. Merck & Co. has a 52-week low of $52.83 and a 52-week high of $66.41.

Merck & Co. (NYSE:MRK) last posted its quarterly earnings results on Friday, February 2nd. The company reported $0.98 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.94 by $0.04. Merck & Co. had a net margin of 6.40% and a return on equity of 28.61%. The business had revenue of $10.43 billion during the quarter, compared to analyst estimates of $10.48 billion. During the same period in the prior year, the firm earned $0.89 earnings per share. The firm’s revenue was up 3.1% compared to the same quarter last year. sell-side analysts predict that Merck & Co. will post 4.16 EPS for the current fiscal year.

The company also recently disclosed a quarterly dividend, which was paid on Friday, April 6th. Investors of record on Thursday, March 15th were issued a $0.48 dividend. The ex-dividend date was Wednesday, March 14th. This represents a $1.92 dividend on an annualized basis and a yield of 3.24%. Merck & Co.’s dividend payout ratio is currently 48.24%.

COPYRIGHT VIOLATION WARNING: “GM Advisory Group Inc. Takes $290,000 Position in Merck & Co. (MRK)” was first posted by The Lincolnian Online and is the property of of The Lincolnian Online. If you are accessing this piece of content on another domain, it was stolen and reposted in violation of United States and international trademark & copyright law. The legal version of this piece of content can be read at https://www.thelincolnianonline.com/2018/04/18/gm-advisory-group-inc-takes-290000-position-in-merck-co-mrk.html.

About Merck & Co.

Merck & Co, Inc provides healthcare solutions worldwide. It operates in four segments: Pharmaceutical, Animal Health, Healthcare Services, and Alliances. The company offers therapeutic and preventive agents to treat cardiovascular diseases, type 2 diabetes, asthma, nasal allergy symptoms, allergic rhinitis, chronic hepatitis C virus, HIV-1 infection, fungal, intra-abdominal infections, hypertension, arthritis and pain, inflammatory, osteoporosis, and fertility diseases.

Institutional Ownership by Quarter for Merck & Co. (NYSE:MRK)

Receive News & Ratings for Merck & Co. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply